Type 2 Diabetes

Reducing systolic blood pressure to less than 120 mmHg lowered the risk of major cardiovascular events for most people with diabetes in the BPROAD trial.

In this episode, hosts explore the most recent updates surrounding GLP-1 receptor agonists, including GLP-1 shortages and long-term data on tirzepatide.

In this episode, hosts discuss the latest developments in GLP-1 receptor agonists, with a particular focus on semaglutide.

In this episode, hosts spotlight updates on Abbott’s Libre 3, Tidepool integration, and Omnipod 5 iOS app, expanding flexibility in diabetes management.

Brandon Arbiter joins the podcast to discuss the latest updates from Tidepool.

In the final part of this 5-part series, Lala-Trindade discusses the findings of the FINEARTS-HF trial and how it might inform use of finerenone.

In part 4 of this 5-part series, discussants explore the influence of recent guidelines on changing standards of CKD care.

In part 3 of this 5-part series, Lerma discusses recent updates in the management of chronic kidney disease in people with type 2 diabetes.

In part 2 of this 5-part series, Lerma and Lala-Trindade discuss the key differences in MoA for nsMRA and MRAs.

In this first of this 5-part series, Lerma and Lala-Trindade discuss the interplay between chronic kidney disease and cardiovascular disease.

A decade after bariatric surgery, most teens maintained weight loss and reduced obesity-related conditions such as type 2 diabetes and hypertension.

Katherine Tuttle, MD, joins the podcast for a deep dive into the latest FLOW data from Kidney Week 2024.

Richard Pratley, MD, discusses how FLOW mortality data informs the use of semaglutide in patients with chronic kidney disease and type 2 diabetes.

Novo Nordisk will present more detailed data in 2025 and plans to file for an expanded label for Rybelsus for this population.

SGLT2 inhibitors appeared effective in improving hepatic inflammation and fibrosis indices in patients with type 2 diabetes and suspected MASLD.

Brian Hansen, president of CGM at Ascensia Diabetes Care, joins the podcast to discuss the FDA clearance of the Eversense 365 CGM.

Our September 2024 monthly recap in endocrinology spotlights regulatory updates, new guidelines, and the latest episodes of Diabetes Dialogue.

Taher Modarressi, MD, sits down with hosts to share tips and practical nuggets for cardiometabolic health specialists to optimize prescription and adherence to newer therapies.

The FDA has approved the Eversense 365, the world’s first 1-year continuous glucose monitor, with US availability expected in late 2024.

A new study found glucagon-like peptide 1 receptor agonist use was associated with a lower risk of cirrhosis complications for patients with MASLD who did not have cirrhosis.

A follow-up to an earlier episode, this episode features a deep dive into the hosts experience with the Dexcom Stelo sensor.

In this episode, hosts discuss availability of the Abbott Lingo CGM and Embecta’s announcement of FDA clearance for their tubeless patch pump with a 300-unit insulin reservoir.

The endocrinology month in review for August 2024 spotlights 6 pieces of major pipeline news or regulatory announcements as well as multiple episodes of Diabetes Dialogue.

A meta-analysis shows GLP-1 RAs and SGLT2 inhibitors offer distinct cardiovascular and kidney benefits in type 2 diabetes.

Rahul Aggarwal, MD, discusses the findings of a SCORED analysis examining sotagliflozin's effects based on diabetes duration.